Dyne Therapeutics, Inc.

NasdaqGS:DYN Stok Raporu

Piyasa değeri: US$2.9b

Dyne Therapeutics Gelecekteki Büyüme

Future kriter kontrolleri 2/6

Dyne Therapeutics kazanç ve gelirin sırasıyla yıllık 12.8% ve 66.8% oranında artacağı tahmin edilmektedir. EPS'nin yıllık 20.5% oranında büyümesi beklenmektedir. Özkaynak kârlılığının 3 yıl içinde -51.3% olacağı tahmin edilmektedir.

Anahtar bilgiler

12.8%

Kazanç büyüme oranı

20.5%

EPS büyüme oranı

Biotechs kazanç büyümesi27.3%
Gelir büyüme oranı66.8%
Gelecekteki özkaynak getirisi-51.3%
Analist kapsamı

Good

Son güncelleme24 Oct 2024

Gelecekteki son büyüme güncellemeleri

Recent updates

Dyne Therapeutics: Management Merry-Go-Round, Shaky Data Rock Wall Street

Sep 04

Companies Like Dyne Therapeutics (NASDAQ:DYN) Are In A Position To Invest In Growth

Aug 14
Companies Like Dyne Therapeutics (NASDAQ:DYN) Are In A Position To Invest In Growth

Dyne Therapeutics: Progress Undenied In DM1 And DMD Trials

May 21

We're Not Very Worried About Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Rate

May 04
We're Not Very Worried About Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Rate

Dyne: H2 2024 Muscle Disease Data Could Boost Value

Mar 05

We're Keeping An Eye On Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Rate

Dec 05
We're Keeping An Eye On Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Rate

Here's Why We're Watching Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Situation

Aug 09
Here's Why We're Watching Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Situation

We're Keeping An Eye On Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Rate

Mar 26
We're Keeping An Eye On Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Rate

We Think Dyne Therapeutics (NASDAQ:DYN) Needs To Drive Business Growth Carefully

Dec 10
We Think Dyne Therapeutics (NASDAQ:DYN) Needs To Drive Business Growth Carefully

Is Dyne Therapeutics (NASDAQ:DYN) In A Good Position To Invest In Growth?

Aug 26
Is Dyne Therapeutics (NASDAQ:DYN) In A Good Position To Invest In Growth?

Dyne wins regulatory nod to start trial for myotonic dystrophy candidate

Jul 12

Dyne stock rises 12% as FDA lifts hold on starting muscle disorder study of DYNE-251

Jul 05

Here's Why We're Watching Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Situation

May 05
Here's Why We're Watching Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Situation

We're Hopeful That Dyne Therapeutics (NASDAQ:DYN) Will Use Its Cash Wisely

Jan 12
We're Hopeful That Dyne Therapeutics (NASDAQ:DYN) Will Use Its Cash Wisely

We Think Dyne Therapeutics (NASDAQ:DYN) Can Afford To Drive Business Growth

Sep 29
We Think Dyne Therapeutics (NASDAQ:DYN) Can Afford To Drive Business Growth

Dyne Therapeutics' chief scientific officer Romesh Subramanian steps down

Jun 02

Here's Why We're Not Too Worried About Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Situation

May 12
Here's Why We're Not Too Worried About Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Situation

Dyne Therapeutics EPS beats by $0.10

May 06

Could The Dyne Therapeutics, Inc. (NASDAQ:DYN) Ownership Structure Tell Us Something Useful?

Jan 27
Could The Dyne Therapeutics, Inc. (NASDAQ:DYN) Ownership Structure Tell Us Something Useful?

Kazanç ve Gelir Büyüme Tahminleri

NasdaqGS:DYN - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
TarihGelirKazançlarSerbest Nakit AkışıFaaliyetlerden NakitAvg. Analist Sayısı
12/31/202611-348-320-2976
12/31/20251-322-295-2679
12/31/2024N/A-272-280-2429
6/30/2024N/A-258-220-219N/A
3/31/2024N/A-257-220-220N/A
12/31/2023N/A-236-189-188N/A
9/30/2023N/A-208-184-182N/A
6/30/2023N/A-189-176-175N/A
3/31/2023N/A-177-152-150N/A
12/31/2022N/A-168-157-154N/A
9/30/2022N/A-181-157-153N/A
6/30/2022N/A-182-141-137N/A
3/31/2022N/A-160-157-152N/A
12/31/2021N/A-149-123-120N/A
9/30/2021N/A-126-114-112N/A
6/30/2021N/A-97-98-96N/A
3/31/2021N/A-77-59-58N/A
12/31/2020N/A-59-48-47N/A
9/30/2020N/A-36-32-30N/A
6/30/2020N/A-28-23-22N/A
3/31/2020N/A-21-18-17N/A
12/31/2019N/A-15-13-12N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: DYN önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Kazançlar ve Piyasa: DYN önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Yüksek Büyüme Kazançları: DYN önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Gelir ve Pazar: DYN şirketinin gelirinin (yıllık 66.8% ) US pazarından (yıllık 8.8% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Geliri: DYN şirketinin gelirinin (yıllık 66.8% ) yıllık 20% dan daha hızlı büyümesi öngörülüyor.


Hisse Başına Kazanç Büyüme Tahminleri


Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: DYN 3 yıl içinde kârsız olması bekleniyor.


Büyüyen şirketleri keşfedin